Posted by Michael Wonder on 12 Dec 2020
CHMP recommends the approvals of Rinvoq (upadacitinib) for the treatment of adults with active psoriatic arthritis and ankylosing spondylitis
10 December 2020 - If approved, Rinvoq will be the first oral, selective and reversible JAK inhibitor approved in three rheumatologic conditions in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
AbbVie today announced that the EMA's CHMP recommended the approval of Rinvoq (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor, for the expanded use in two additional rheumatic indications: the treatment of adult patients with active psoriatic arthritis and adult patients with active ankylosing spondylitis.
The CHMP positive opinions are based on results from three pivotal clinical studies in which Rinvoq demonstrated efficacy across multiple measures of disease activity.
